Equities analysts expect Merus NV (NASDAQ:MRUS) to announce sales of $7.82 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Merus’ earnings, with the lowest sales estimate coming in at $6.78 million and the highest estimate coming in at $8.66 million. Merus reported sales of $7.57 million in the same quarter last year, which indicates a positive year-over-year growth rate of 3.3%. The business is scheduled to announce its next earnings report on Thursday, December 26th.
According to Zacks, analysts expect that Merus will report full-year sales of $31.88 million for the current year, with estimates ranging from $30.89 million to $32.86 million. For the next year, analysts expect that the business will report sales of $49.17 million, with estimates ranging from $32.03 million to $81.28 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Merus.
Merus (NASDAQ:MRUS) last posted its quarterly earnings data on Monday, August 19th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.03). The firm had revenue of $6.27 million for the quarter, compared to analysts’ expectations of $8.62 million. Merus had a negative return on equity of 41.68% and a negative net margin of 104.10%.
MRUS traded down $0.86 during mid-day trading on Friday, reaching $15.51. 82,423 shares of the stock were exchanged, compared to its average volume of 37,231. The stock has a market capitalization of $371.17 million, a PE ratio of -8.43 and a beta of 0.24. The company has a 50 day moving average price of $17.24 and a two-hundred day moving average price of $15.47. Merus has a 1 year low of $11.00 and a 1 year high of $20.95.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRUS. Artal Group S.A. lifted its holdings in Merus by 16.7% during the second quarter. Artal Group S.A. now owns 350,000 shares of the biotechnology company’s stock valued at $5,128,000 after purchasing an additional 50,000 shares during the last quarter. Athanor Capital LP purchased a new stake in Merus during the second quarter valued at about $334,000. JPMorgan Chase & Co. lifted its holdings in Merus by 63.5% during the second quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 3,389 shares during the last quarter. Finally, Morgan Stanley lifted its holdings in Merus by 3.1% during the second quarter. Morgan Stanley now owns 92,776 shares of the biotechnology company’s stock valued at $1,359,000 after purchasing an additional 2,788 shares during the last quarter. 52.00% of the stock is currently owned by institutional investors and hedge funds.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
See Also: What is the NASDAQ?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.